Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
SAN DIEGO, Sept. 5, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Company Chairman and CEO, Jim Joyce has accepted an invitation to present at the Exosomes and Circulating Biomarkers 2013 Summit on September 12th. Mr. Joyce's presentation is entitled; "Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer." The presentation will highlight the clinical advancement of the Aethlon Hemopurifier® in treating hepatitis c virus (HCV) and discuss the opportunity to expand therapeutic indications to include cancer based on targeting the elimination of circulating tumor-secreted exosomes. The conference will be held at the Town and Country Resort Hotel in San Diego, California.
Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). Under the IDE, Aethlon will enroll ten end stage renal disease (ESRD) patients infected with HCV as part of a feasibility study to demonstrate Hemopurifier safety. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and other disease conditions.
The conference abstract of the presentation follows:
Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer on 9/12/13 at 3:45pm pacific.
The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.
In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's future clinical programs or provide market clearance of the Company's products, future human studies whether revenue or non-revenue generating from either compassionate use or non-compassionate use of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or sepsis therapies or as a standalone cancer or hepatitis C therapy or standalone sepsis therapy, the approval of the Company's technologies or products as a treatment against pandemic threats, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
James A. Joyce
Chairman and CEO
Chief Financial Officer
SOURCE Aethlon Medical, Inc.
More by this Source
Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries
Mar 05, 2014, 08:29 ET
Aethlon Medical® Announces Agreement with DaVita Clinical Research®
Feb 26, 2014, 08:03 ET
Aethlon Medical to Present at Biotech Showcase Investor Conference
Jan 07, 2014, 09:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.